Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2014 3
2015 2
2016 1
2017 3
2018 2
2019 4
2020 5
2021 6
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS, Filippatos G, Gniot J, Fu M, Gullestad L, Howlett JG, Nicholls SJ, Redon J, Schenkenberger I, Silva-Cardoso J, Störk S, Krzysztof Wranicz J, Savarese G, Brueckmann M, Jamal W, Nordaby M, Peil B, Ritter I, Ustyugova A, Zeller C, Salsali A, Anker SD. Abraham WT, et al. Among authors: ustyugova a. Eur Heart J. 2021 Feb 11;42(6):700-710. doi: 10.1093/eurheartj/ehaa943. Eur Heart J. 2021. PMID: 33351892 Clinical Trial.
Healthcare resource utilization in patients treated with empagliflozin in East Asia.
Sheu WH, Seino Y, Tan EC, Yabe D, Ha KH, Nangaku M, Chung WJ, Node K, Yasui A, Lei WY, Lee S, Ustyugova A, Klement R, Deruaz-Luyet A, Kyaw MH, Kim DJ; EMPRISE East Asia study group. Sheu WH, et al. Among authors: ustyugova a. J Diabetes Investig. 2022 May;13(5):810-821. doi: 10.1111/jdi.13728. Epub 2022 Jan 11. J Diabetes Investig. 2022. PMID: 34859609 Free PMC article.
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial.
Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A. Reifsnider OS, et al. Among authors: ustyugova a. Am J Kidney Dis. 2022 Jun;79(6):796-806. doi: 10.1053/j.ajkd.2021.09.014. Epub 2021 Nov 6. Am J Kidney Dis. 2022. PMID: 34752913 Free article. Clinical Trial.
Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
Thomsen RW, Knudsen JS, Kahlert J, Baggesen LM, Lajer M, Holmgaard PH, Vedin O, Ustyugova A, Sørensen HT. Thomsen RW, et al. Among authors: ustyugova a. J Am Heart Assoc. 2021 Jun;10(11):e019356. doi: 10.1161/JAHA.120.019356. Epub 2021 May 25. J Am Heart Assoc. 2021. PMID: 34032121 Free PMC article.
Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark.
Thomsen RW, Christensen LWB, Kahlert J, Knudsen JS, Ustyugova A, Sandgaard S, Holmgaard P, Ehlers LH, Sørensen HT. Thomsen RW, et al. Among authors: ustyugova a. Diabetes Ther. 2022 Dec;13(11-12):1891-1906. doi: 10.1007/s13300-022-01323-y. Epub 2022 Oct 31. Diabetes Ther. 2022. PMID: 36315384 Free PMC article.
Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
Pollack CV Jr, Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, Kam CW, Kleine E, Levy JH, Sellke FW, Steiner T, Ustyugova A, Weitz JI. Pollack CV Jr, et al. Among authors: ustyugova a. J Med Econ. 2017 May;20(5):435-442. doi: 10.1080/13696998.2016.1273229. Epub 2017 Jan 17. J Med Econ. 2017. PMID: 27981865 Free article. Clinical Trial.
28 results